-
Integrated Proteomic and Metabolomic prediction of Term Preeclampsia.
Bahado-Singh R, Poon LC, Yilmaz A, Syngelaki A, Turkoglu O, Kumar P, Kirma J, Allos M, Accurti V, Li J, Zhao P, Graham SF, Cool DR, Nicolaides K.
Sci Rep 2017;7:16189. pdf -
Proteomic Biomarkers of Preterm Birth Risk in Women with Polycystic Ovary Syndrome (PCOS): A Systematic Review and Biomarker Database Integration.
Galazis N, Docheva N, Nicolaides KH, Atiomo W.
PLoS One 2013;8:e53801. -
Are Serum Protein Biomarkers Derived from Proteomic Analysis Useful in Screening for Trisomy 21 at 11-13 Weeks?
Mastricci AL, Akolekar R, Kuppusamy R, Ahmed M, Nicolaides KH.
Fetal Diagn Ther 2011;30:53-9. -
Maternal serum placental protein 13 at eleven to thirteen weeks in chromosomally abnormal pregnancies.
Akolekar R, Pérez Penco JM, Skyfta E, Rodríguez Calvo J, Nicolaides KH.
Fetal Diagn Ther 2010;27:72-7. -
Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia.
Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH.
Prenat Diagn 2009;29:1103-8. -
A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound.
Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS.
Ultrasound Obstet Gynecol 2006;27:13-7.